Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state situation on Parkinson’s disease in Uzbekistan.
Background: Uzbekistan has 35 million population, largest in the region, but the diversity of the medications and treatment options are too low. We have only one Pramipexole and Ropinirol distributors in market. In addition, we have CRW stereotactic frame but DBS is not available in Uzbekistan.
Method: 45 Patients with tremor dominant Parkinson’s disease was examined and diagnosis confirmed by single specialist and was under observership for 3 to 18 month. All patients also was examined by psychiatrist, the patients do not have cognitive problems and hallucinations.
Average age of patients – 59,3 (±4,4). Sex: Male – 28 (62,2%), Female – 17 (37,8%). Average Parkinson’s disease anamnesis – 5 years (2-8 years). All Dopa agonist were added after patients were receiving essential dose of Levodopa (500-2000 mg).
From 45 Patients, 25 were prescribed Pramipexole and 20 Ropinirol.
For measurement of the tremor I have used UPDRS III 3.15 – 3.18 parts.
Results: Starting dosage of the Pramipexole were 0,5 mg in average 10 month dosage was raised up to average 2,4 mg (1,25 mg – 3,25 mg,), tremor reduced from 3,4 to 1,0. Starting dosage of the Ropinirol were 4 mg in average 11 month dosage was raised up to average 16 mg (12mg -24mg) tremor reduced tremor from 3,7 to 0,8.
Conclusion: The results of this study showed that: 1) In testing group Ropinirol had slightly better effect in tremor. 2) That in the in low-income countries with restricted medications most of the patients can improve their quality of life with combination of only Levodopa and single dopa agonist. Moreover, situation with the restricted diversity of the medications worsen general condition, and the absence of DBS does not lead situation to the positive point. I hope in near future companies will allow to register DBS in Uzbekistan.
To cite this abstract in AMA style:
B. Mukhammedaminov. Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications. [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/comparing-pramipexole-and-ropinirole-in-the-management-of-the-tremor-in-parkinsons-disease-in-the-low-income-country-and-environment-of-restricted-medications/. Accessed May 14, 2025.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/comparing-pramipexole-and-ropinirole-in-the-management-of-the-tremor-in-parkinsons-disease-in-the-low-income-country-and-environment-of-restricted-medications/